Loading...

Kathryn Phillips, PhD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentClinical Pharmacy
Address3333 Calif. St,Laurel Heights
San Francisco CA 94118
Phone415-502-8271
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    UCSFPost-doctoral fellowship
    Kennedy School of Government Harvard UniversityMC-MPA
    University of Texas at AustinBA
    Collapse Awards and Honors
    Harvard/Dept of Navy (civilian)1985  - 1986Training Award for mid-career Master's Degree
    UC Berkeley1987  - 1988UC Berkeley Graduate Fellowship
    UC-Berkeley1989  - 1989Outstanding Graduate Student Instructor
    Am J Prev Med1999  - 1999Commendation for outstanding journal reviews
    Univ of CT2003  - 200350 Most Cited HIV Behavioral Researchers in Past Decade
    Research Triangle Institute2010  - 2010Most cited article award
    Bellagio Center Italy2016Rockefeller Foundation Residency

    Collapse Overview 
    Collapse Overview
    Kathryn A. Phillips, PhD, a health services researcher and health economist and leader in the application of new technologies to improve healthcare, is the founding director of the Center for Translational and Policy Research on Personalized Medicine (TRANSPERS) in the School of Pharmacy at the University of California, San Francisco (UCSF). She is also a professor of health economics and health services research in the Department of Clinical Pharmacy at UCSF, with additional appointments in the UCSF Philip R. Lee Institute for Health Policy Studies and UCSF Helen Diller Family Comprehensive Cancer Center

    Kathryn focuses on the value of new technologies and how to most effectively and efficiently implement them into health care. Her core specialty is personalized (or precision) medicine — a new era of healthcare where medical interventions can be tailored to individual patients based on their unique genetic make-up. Her work spans multiple disciplines, including basic, clinical and social sciences, and brings together leading experts in academia, industry, healthcare, payers, and government. Kathryn led one of the earliest studies on the societal implications of pharmacogenomics, underscoring its potential to reduce the incidence of adverse drug reactions (JAMA, 2001). Her pioneering research on the application of health services research to personalized medicine has revealed insights on how to bridge the gap between emerging technologies and their use in the clinic. Kathryn has also conducted seminal work on HIV, as her analysis of HIV home testing informed the FDA’s decision to approve the first home collection HIV test (New England Journal of Medicine, 1995).

    Kathryn has published ~150 peer-reviewed articles in major journals, including JAMA, the New England Journal of Medicine, and Health Affairs and has had continuous funding from the US. National Institutes of Health as a principal investigator for 25 years. She currently serves on the editorial boards of the journal Health Affairs (rated as the top policy journal), Value in Health (a leading outcomes research journal), and all of the leading journals on personalized medicine. Kathryn has served on national and international scientific advisory committees and workshops including work Board of Directors for GenomeCanada, National Academy of Medicine, Food and Drug Administration, Centers for Disease Control and Prevention, and the President’s Council of Advisors on Science and Technology. She has also served as an advisor to various international and industry organizations, including more than 35 biotechnology companies and venture capital firms. She was recently awarded a Rockefeller Foundation global and worked with thethe Patient-Centered Outcomes Research Institute (PCORI) - the largest funder of comparative effectiveness research in the world - developing a research agenda on personalized/precision medicine.


    Collapse Research 
    Collapse Research Activities and Funding
    Coverage, Price, and Reimbursement for Multigene Tests for Cancer and Related Conditions
    NIH/NCI R01CA221870Jul 1, 2018 - Jun 30, 2021
    Role: Principal Investigator
    Risk-Benefit Trade-Offs for Whole Genome Sequencing
    NIH/NHGRI R01HG007063Feb 15, 2013 - Jan 31, 2017
    Role: Principal Investigator
    Personalized Medicine for Colorectal and Breast Cancer
    NIH/NCI P01CA130818Sep 16, 2008 - Aug 31, 2013
    Role: Principal Investigator
    Screening for Colorectal Cancer: An Integrated Approach
    NIH/NCI R01CA101849Apr 28, 2004 - Mar 31, 2009
    Role: Principal Investigator
    USE OF CANCER SCREENING IN A MANAGED CARE ENVIRONMENT
    NIH/NCI R01CA081130Feb 1, 2000 - Apr 30, 2004
    Role: Principal Investigator
    UTILIZATION AND COST EFFECTIVENESS OF NEW HIV TESTS
    NIH/NIAID R01AI043744Jul 1, 1999 - Aug 31, 2003
    Role: Principal Investigator
    EFFECTIVENESS AND COST-EFFECTIVENESS OF HIV TESTING
    NIH/NIAID R29AI034864Dec 1, 1993 - Nov 30, 1999
    Role: Principal Investigator
    GOVERNMENT INTERVENTION AND UTILIZATION OF HIV SCREENING
    AHRQ R03HS006629Sep 1, 1990 - Aug 31, 1991
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Featured Publications
    Collapse Websites
    Collapse In The News
    Collapse Featured Presentations
    Collapse Featured Videos

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Douglas MP, Parker SL, Trosman JR, Slavotinek AM, Phillips K. Private payer coverage policies for exome sequencing (ES) in pediatric patients: trends over time and analysis of evidence cited. Genet Med. 2018 Jul 12. PMID: 29997388.
      View in: PubMed
    2. Phillips K, Deverka PA, Hooker GW, Douglas MP. Genetic Test Availability And Spending: Where Are We Now? Where Are We Going? Health Aff (Millwood). 2018 May; 37(5):710-716. PMID: 29733704.
      View in: PubMed
    3. Ginsburg GS, Phillips K. Precision Medicine: From Science To Value. Health Aff (Millwood). 2018 May; 37(5):694-701. PMID: 29733705.
      View in: PubMed
    4. Phillips K, Trosman JR, Deverka PA, Quinn B, Tunis S, Neumann PJ, Chambers JD, Garrison LP, Douglas MP, Weldon CB. Insurance coverage for genomic tests. Science. 2018 04 20; 360(6386):278-279. PMID: 29674586.
      View in: PubMed
    5. Phillips K. Evolving Payer Coverage Policies on Genomic Sequencing Tests: Beginning of the End or End of the Beginning? JAMA. 2018 Apr 16. PMID: 29710095.
      View in: PubMed
    6. Christensen KD, Vassy JL, Phillips K, Blout CL, Azzariti DR, Lu CY, Robinson JO, Lee K, Douglas MP, Yeh JM, Machini K, Stout NK, Rehm HL, McGuire AL, Green RC, Dukhovny D. Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial. Genet Med. 2018 Mar 22. PMID: 29565423.
      View in: PubMed
    7. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips K. Corrigendum: What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2018 Jan; 20(1):165. PMID: 29261179.
      View in: PubMed
    8. Chambers JD, Saret CJ, Anderson JE, Deverka PA, Douglas MP, Phillips K. EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. Int J Technol Assess Health Care. 2017 Jan; 33(4):534-540. PMID: 29065945.
      View in: PubMed
    9. Phillips K, Deverka PA, Trosman JR, Douglas MP, Chambers JD, Weldon CB, Dervan AP. Payer coverage policies for multigene tests. Nat Biotechnol. 2017 Jul 12; 35(7):614-617. PMID: 28700544.
      View in: PubMed
    10. Marshall DA, MacDonald KV, Robinson JO, Barcellos LF, Gianfrancesco M, Helm M, McGuire A, Green RC, Douglas MP, Goldman MA, Phillips K. The price of whole-genome sequencing may be decreasing, but who will be sequenced? Per Med. 2017 May; 14(3):203-211. PMID: 28993792.
      View in: PubMed
    11. Phillips K, Deverka PA, Sox HC, Khoury MJ, Sandy LG, Ginsburg GS, Tunis SR, Orlando LA, Douglas MP. Making genomic medicine evidence-based and patient-centered: a structured review and landscape analysis of comparative effectiveness research. Genet Med. 2017 Oct; 19(10):1081-1091. PMID: 28406488.
      View in: PubMed
    12. Trosman JR, Weldon CB, Douglas MP, Kurian AW, Kelley RK, Deverka PA, Phillips K. Payer Coverage for Hereditary Cancer Panels: Barriers, Opportunities, and Implications for the Precision Medicine Initiative. J Natl Compr Canc Netw. 2017 02; 15(2):219-228. PMID: 28188191.
      View in: PubMed
    13. Phillips K, Douglas MP, Trosman JR, Marshall DA. "What Goes Around Comes Around": Lessons Learned from Economic Evaluations of Personalized Medicine Applied to Digital Medicine. Value Health. 2017 01; 20(1):47-53. PMID: 28212968.
      View in: PubMed
    14. Trosman JR, Weldon CB, Douglas MP, Deverka PA, Watkins JB, Phillips K. Decision Making on Medical Innovations in a Changing Health Care Environment: Insights from Accountable Care Organizations and Payers on Personalized Medicine and Other Technologies. Value Health. 2017 01; 20(1):40-46. PMID: 28212967.
      View in: PubMed
    15. Phillips K. Assessing the Value and Implications of Personalized/Precision Medicine and the "Lessons Learned" for Emerging Technologies: An Introduction. Value Health. 2017 01; 20(1):30-31. PMID: 28212965.
      View in: PubMed
    16. Dervan AP, Deverka PA, Trosman JR, Weldon CB, Douglas MP, Phillips K. Payer decision making for next-generation sequencing-based genetic tests: insights from cell-free DNA prenatal screening. Genet Med. 2017 05; 19(5):559-567. PMID: 27657682.
      View in: PubMed
    17. Marshall DA, Gonzalez JM, Johnson FR, MacDonald KV, Pugh A, Douglas MP, Phillips K. What are people willing to pay for whole-genome sequencing information, and who decides what they receive? Genet Med. 2016 12; 18(12):1295-1302. PMID: 27253734.
      View in: PubMed
    18. Phillips K, Schleifer D, Hagelskamp C. Most Americans Do Not Believe That There Is An Association Between Health Care Prices And Quality Of Care. Health Aff (Millwood). 2016 Apr; 35(4):647-53. PMID: 27044965.
      View in: PubMed
    19. Clain E, Trosman JR, Douglas MP, Weldon CB, Phillips K. Availability and payer coverage of BRCA1/2 tests and gene panels. Nat Biotechnol. 2015 Sep; 33(9):900-2. PMID: 26348951; PMCID: PMC4625918.
    20. Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips K. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med. 2016 Feb; 18(2):111-6. PMID: 25996638; PMCID: PMC4654986.
    21. Phillips K, Ladabaum U, Pletcher MJ, Marshall DA, Douglas MP. Key emerging themes for assessing the cost-effectiveness of reporting incidental findings. Genet Med. 2015 Apr; 17(4):314-5. PMID: 25835195; PMCID: PMC4395812.
    22. Trosman JR, Weldon CB, Kelley RK, Phillips K. Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in. J Natl Compr Canc Netw. 2015 Mar; 13(3):311-8. PMID: 25736008; PMCID: PMC4372087.
    23. Foster DG, Biggs MA, Phillips K, Grindlay K, Grossman D. Potential public sector cost-savings from over-the-counter access to oral contraceptives. Contraception. 2015 May; 91(5):373-9. PMID: 25732570.
      View in: PubMed
    24. Knight SJ, Mohamed AF, Marshall DA, Ladabaum U, Phillips K, Walsh JM. Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online Sample. Med Decis Making. 2015 01 14. PMID: 25589525.
      View in: PubMed
    25. Phillips K, Pletcher MJ, Ladabaum U. Is the ``$1000 Genome'' really $1000? Understanding the full benefits and costs of genomic sequencing. Technol Health Care. 2015; 23(3):373-9. PMID: 25669213; PMCID: PMC4527943.
    26. Garfeld S, Douglas MP, MacDonald KV, Marshall DA, Phillips K. Consumer familiarity, perspectives and expected value of personalized medicine with a focus on applications in oncology. Per Med. 2015 Jan 01; 12(1):13-22. PMID: 25620993.
      View in: PubMed
    27. Phillips K, Trosman JR, Kelley RK, Pletcher MJ, Douglas MP, Weldon CB. Genomic sequencing: assessing the health care system, policy, and big-data implications. Health Aff (Millwood). 2014 Jul; 33(7):1246-53. PMID: 25006153; PMCID: PMC4113721.
    28. Balakrishnan N, Pritchard J, Ericson M, Grindem C, Phillips K, Jennings S, Mathews K, Tran H, Birkenheuer AJ, Breitschwerdt EB. Prostatitis, steatitis, and diarrhea in a dog following presumptive flea-borne transmission of Bartonella henselae. J Clin Microbiol. 2014 Sep; 52(9):3447-52. PMID: 24920774; PMCID: PMC4313127.
    29. Phillips K, Ann Sakowski J, Trosman J, Douglas MP, Liang SY, Neumann P. The economic value of personalized medicine tests: what we know and what we need to know. Genet Med. 2014 Mar; 16(3):251-7. PMID: 24232413; PMCID: PMC3949119.
    30. Wang G, Kuppermann M, Kim B, Phillips K, Ladabaum U. Influence of patient preferences on the cost-effectiveness of screening for lynch syndrome. J Oncol Pract. 2012 May; 8(3 Suppl):e24s-30s. PMID: 22942831; PMCID: PMC3348599.
    31. Beattie MS, Wang G, Phillips K. Differences in US healthcare coverage policies in BRCA testing and potential implications. Per Med. 2012 Jan; 9(1):5-8. PMID: 29783285.
      View in: PubMed
    32. Wang G, Beattie MS, Ponce NA, Phillips K. Eligibility criteria in private and public coverage policies for BRCA genetic testing and genetic counseling. Genet Med. 2011 Dec; 13(12):1045-50. PMID: 21844812; PMCID: PMC4537294.
    33. Elkin EB, Marshall DA, Kulin NA, Ferrusi IL, Hassett MJ, Ladabaum U, Phillips K. Economic evaluation of targeted cancer interventions: critical review and recommendations. Genet Med. 2011 Oct; 13(10):853-60. PMID: 21637102; PMCID: PMC3774033.
    34. Liang SY, Phillips K, Wang G, Keohane C, Armstrong J, Morris WM, Haas JS. Tradeoffs of using administrative claims and medical records to identify the use of personalized medicine for patients with breast cancer. Med Care. 2011 Jun; 49(6):e1-8. PMID: 21422962; PMCID: PMC3383782.
    35. Trosman JR, Van Bebber SL, Phillips K. Health technology assessment and private payers' coverage of personalized medicine. J Oncol Pract. 2011 May; 7(3 Suppl):18s-24s. PMID: 21886515; PMCID: PMC3092460.
    36. Haas JS, Phillips K, Liang SY, Hassett MJ, Keohane C, Elkin EB, Armstrong J, Toscano M. Genomic testing and therapies for breast cancer in clinical practice. J Oncol Pract. 2011 May; 7(3 Suppl):e1s-7s. PMID: 21886507; PMCID: PMC3092459.
    37. Trosman JR, Van Bebber SL, Phillips K. Health technology assessment and private payers's coverage of personalized medicine. Am J Manag Care. 2011 May; 17 Suppl 5 Developing:SP53-60. PMID: 21711078.
      View in: PubMed
    38. Johnson FR, Mohamed AF, Ozdemir S, Marshall DA, Phillips K. How does cost matter in health-care discrete-choice experiments? Health Econ. 2011 Mar; 20(3):323-30. PMID: 20217834; PMCID: PMC3918954.
    39. Kelley RK, Van Bebber SL, Phillips K, Venook AP. Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):13-25. PMID: 21233242; PMCID: PMC3695822.
    40. Trosman JR, Van Bebber SL, Phillips K. Coverage policy development for personalized medicine: private payer perspectives on developing policy for the 21-gene assay. J Oncol Pract. 2010 Sep; 6(5):238-42. PMID: 21197187; PMCID: PMC2936466.
    41. Van Bebber SL, Trosman JR, Liang SY, Wang G, Marshall DA, Knight S, Phillips K. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice. Per Med. 2010 Jul; 7(4):427-439. PMID: 21857867.
      View in: PubMed
    42. Marshall DA, Johnson FR, Kulin NA, Ozdemir S, Walsh JM, Marshall JK, Van Bebber S, Phillips K. How do physician assessments of patient preferences for colorectal cancer screening tests differ from actual preferences? A comparison in Canada and the United States using a stated-choice survey. Health Econ. 2009 Dec; 18(12):1420-39. PMID: 19191268; PMCID: PMC3964796.
    43. Phillips K, Marshall DA, Haas JS, Elkin EB, Liang SY, Hassett MJ, Ferrusi I, Brock JE, Van Bebber SL. Clinical practice patterns and cost effectiveness of human epidermal growth receptor 2 testing strategies in breast cancer patients. Cancer. 2009 Nov 15; 115(22):5166-74. PMID: 19753618; PMCID: PMC2783254.
    44. Ferrusi IL, Marshall DA, Kulin NA, Leighl NB, Phillips K. Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per Med. 2009 Mar; 6(2):193-215. PMID: 20668661.
      View in: PubMed
    45. Payne K, Newman WG, Gurwitz D, Ibarreta D, Phillips K. TPMT testing in azathioprine: a 'cost-effective use of healthcare resources'? Per Med. 2009 Jan; 6(1):103-113. PMID: 29783387.
      View in: PubMed
    46. Phillips K, Liang SY, Van Bebber S. Challenges to the translation of genomic information into clinical practice and health policy: Utilization, preferences and economic value. Curr Opin Mol Ther. 2008 Jun; 10(3):260-6. PMID: 18535933; PMCID: PMC2910510.
    47. Haas JS, Fitzmaurice G, Brawarsky P, Liang SY, Hiatt RA, Klabunde CN, Brown ML, Phillips K. Association of regional variation in primary care physicians' colorectal cancer screening recommendations with individual use of colorectal cancer screening. Prev Chronic Dis. 2007 Oct; 4(4):A90. PMID: 17875265; PMCID: PMC2099288.
    48. Marshall DA, Johnson FR, Phillips K, Marshall JK, Thabane L, Kulin NA. Measuring patient preferences for colorectal cancer screening using a choice-format survey. Value Health. 2007 Sep-Oct; 10(5):415-30. PMID: 17888107.
      View in: PubMed
    49. Issa AM, Phillips K, Van Bebber S, Nidamarthy HG, Lasser KE, Haas JS, Alldredge BK, Wachter RM, Bates DW. Drug withdrawals in the United States: a systematic review of the evidence and analysis of trends. Curr Drug Saf. 2007 Sep; 2(3):177-85. PMID: 18690965.
      View in: PubMed
    50. Van Bebber SL, Liang SY, Phillips K, Marshall D, Walsh J, Kulin N. Valuing personalized medicine: willingness to pay for genetic testing for colorectal cancer risk. Per Med. 2007 Aug; 4(3):341-350. PMID: 29788665.
      View in: PubMed
    51. Phillips K, Liang SY, Ladabaum U, Haas J, Kerlikowske K, Lieberman D, Hiatt R, Nagamine M, Van Bebber SL. Trends in colonoscopy for colorectal cancer screening. Med Care. 2007 Feb; 45(2):160-7. PMID: 17224779.
      View in: PubMed
    52. Afable-Munsuz A, Gould H, Stewart F, Phillips K, Van Bebber SL, Moore C. Provider practice models for and costs of delivering medication abortion -- evidence from 11 US abortion care settings. Contraception. 2007 Jan; 75(1):45-51. PMID: 17161124.
      View in: PubMed
    53. Phillips K, Van Bebber SL, Issa AM. Initial development of an evidence base for personalized medicine's translation to clinical practice and health policy. Per Med. 2006 Nov; 3(4):411-414. PMID: 29788589.
      View in: PubMed
    54. Issa AM, Todd Weiss L, Tufail W, Phillips K, Van Bebber SL. Innovation in personalized medicine: BiDil® as a case study for integrating clinical and policy developments. Per Med. 2006 Nov; 3(4):421-427. PMID: 29788596.
      View in: PubMed
    55. Van Bebber SL, Keegan HL, Phillips K, Issa AM. Novel personalized medicine technology: UGT1A1 testing for irinotecan as a case study. Per Med. 2006 Nov; 3(4):415-419. PMID: 29788595.
      View in: PubMed
    56. Liang SY, Phillips K, Nagamine M, Ladabaum U, Haas JS. Rates and predictors of colorectal cancer screening. Prev Chronic Dis. 2006 Oct; 3(4):A117. PMID: 16978492; PMCID: PMC1779281.
    57. Keenan PS, Neumann PJ, Phillips K. Biotechnology and Medicare's new technology policy: lessons from three case studies. Health Aff (Millwood). 2006 Sep-Oct; 25(5):1260-9. PMID: 16966721.
      View in: PubMed
    58. Phillips K. The intersection of biotechnology and pharmacogenomics: health policy implications. Health Aff (Millwood). 2006 Sep-Oct; 25(5):1271-80. PMID: 16966723.
      View in: PubMed
    59. Phillips K, Van Bebber S, Marshall D, Walsh J, Thabane L. A review of studies examining stated preferences for cancer screening. Prev Chronic Dis. 2006 Jul; 3(3):A75. PMID: 16776876; PMCID: PMC1636712.
    60. Phillips K, Van Bebber SL. Regulatory perspectives on pharmacogenomics: a review of the literature on key issues faced by the United States Food and Drug Administration. Med Care Res Rev. 2006 Jun; 63(3):301-26. PMID: 16651395.
      View in: PubMed
    61. Phillips K, Van Bebber S, Issa AM. Diagnostics and biomarker development: priming the pipeline. Nat Rev Drug Discov. 2006 Jun; 5(6):463-9. PMID: 16718275.
      View in: PubMed
    62. Gellad WF, Huskamp HA, Phillips K, Haas JS. How the new medicare drug benefit could affect vulnerable populations. Health Aff (Millwood). 2006 Jan-Feb; 25(1):248-55. PMID: 16403761; PMCID: PMC1403812.
    63. Van Bebber SL, Phillips K, Weitz TA, Gould H, Stewart F. Patient costs for medication abortion: results from a study of five clinical practices. Womens Health Issues. 2006 Jan-Feb; 16(1):4-13. PMID: 16487919.
      View in: PubMed
    64. Phillips K, Ackerman MJ, Sakowski J, Berul CI. Cost-effectiveness analysis of genetic testing for familial long QT syndrome in symptomatic index cases. Heart Rhythm. 2005 Dec; 2(12):1294-300. PMID: 16360080.
      View in: PubMed
    65. Phillips K, Liang SY, Haas JS, Stebbins M, Alldredge BK. Prescription drug dispensing limits and patterns. Manag Care Interface. 2005 Jul; 18(7):41-6. PMID: 16060485.
      View in: PubMed
    66. Phillips K, Van Bebber SL. Measuring the value of pharmacogenomics. Nat Rev Drug Discov. 2005 Jun; 4(6):500-9. PMID: 15915153.
      View in: PubMed
    67. Phillips K, Van Bebber SL. A systematic review of cost-effectiveness analyses of pharmacogenomic interventions. Pharmacogenomics. 2004 Dec; 5(8):1139-49. PMID: 15584880.
      View in: PubMed
    68. Baker LC, Phillips K, Haas JS, Liang SY, Sonneborn D. The effect of area HMO market share on cancer screening. Health Serv Res. 2004 Dec; 39(6 Pt 1):1751-72. PMID: 15533185; PMCID: PMC1361096.
    69. Haggstrom DA, Phillips K, Liang SY, Haas JS, Tye S, Kerlikowske K. Variation in screening mammography and Papanicolaou smear by primary care physician specialty and gatekeeper plan (United States). Cancer Causes Control. 2004 Nov; 15(9):883-92. PMID: 15577290.
      View in: PubMed
    70. Phillips K, Veenstra DL, Ramsey SD, Van Bebber SL, Sakowski J. Genetic testing and pharmacogenomics: issues for determining the impact to healthcare delivery and costs. Am J Manag Care. 2004 Jul; 10(7 Pt 1):425-32. PMID: 15298364.
      View in: PubMed
    71. Phillips K, Haas JS, Liang SY, Baker LC, Tye S, Kerlikowske K, Sakowski J, Spetz J. Are gatekeeper requirements associated with cancer screening utilization? Health Serv Res. 2004 Feb; 39(1):153-78. PMID: 14965082; PMCID: PMC1360999.
    72. Liang SY, Phillips K, Tye S, Haas JS, Sakowski J. Does patient cost sharing matter? Its impact on recommended versus controversial cancer screening services. Am J Manag Care. 2004 Feb; 10(2 Pt 1):99-107. PMID: 15011810.
      View in: PubMed
    73. Tye S, Phillips K, Liang SY, Haas JS. Moving beyond the typologies of managed care: the example of health plan predictors of screening mammography. Health Serv Res. 2004 Feb; 39(1):179-206. PMID: 14965083; PMCID: PMC1361000.
    74. Phillips K, Stotland NE, Liang SY, Spetz J, Haas JS, Oren E. Out-of-pocket expenditures for oral contraceptives and number of packs per purchase. J Am Med Womens Assoc (1972). 2004; 59(1):36-42. PMID: 14768985.
      View in: PubMed
    75. Haas JS, Lee LB, Kaplan CP, Sonneborn D, Phillips K, Liang SY. The association of race, socioeconomic status, and health insurance status with the prevalence of overweight among children and adolescents. Am J Public Health. 2003 Dec; 93(12):2105-10. PMID: 14652342; PMCID: PMC1448160.
    76. Phillips K. Important step forward in HIV-testing technologies [correction of technolgies]. Am J Prev Med. 2003 Aug; 25(2):167. PMID: 12880887.
      View in: PubMed
    77. Phillips K, Veenstra D, Van Bebber S, Sakowski J. An introduction to cost-effectiveness and cost-benefit analysis of pharmacogenomics. Pharmacogenomics. 2003 May; 4(3):231-9. PMID: 12718713.
      View in: PubMed
    78. Phillips K, Chen JL. Willingness to use instant home HIV tests: data from the California Behavioral Risk Factor Surveillance Survey. Am J Prev Med. 2003 May; 24(4):340-8. PMID: 12726872.
      View in: PubMed
    79. Haas JS, Phillips K, Baker LC, Sonneborn D, McCulloch CE. Is the prevalence of gatekeeping in a community associated with individual trust in medical care? Med Care. 2003 May; 41(5):660-8. PMID: 12719690.
      View in: PubMed
    80. Phillips K, Bayer R, Chen JL. New Centers for Disease Control and Prevention's guidelines on HIV counseling and testing for the general population and pregnant women. J Acquir Immune Defic Syndr. 2003 Feb 01; 32(2):182-91. PMID: 12571528.
      View in: PubMed
    81. Phillips K, Spetz J, Haas JS. Viagra and contraceptives. Health Aff (Millwood). 2003 Jan-Feb; 22(1):277. PMID: 12528859.
      View in: PubMed
    82. Phillips K, Johnson FR, Maddala T. Measuring what people value: a comparison of "attitude" and "preference" surveys. Health Serv Res. 2002 Dec; 37(6):1659-79. PMID: 12546291; PMCID: PMC1464045.
    83. Phillips K, Maddala T, Johnson FR. Measuring preferences for health care interventions using conjoint analysis: an application to HIV testing. Health Serv Res. 2002 Dec; 37(6):1681-705. PMID: 12546292; PMCID: PMC1464051.
    84. Haas JS, Phillips K, Sonneborn D, McCulloch CE, Liang SY. Effect of managed care insurance on the use of preventive care for specific ethnic groups in the United States. Med Care. 2002 Sep; 40(9):743-51. PMID: 12218765.
      View in: PubMed
    85. Oren E, McCart G, Phillips K. Evaluating the potential impact of pharmacogenomics on ADRs. J Manag Care Pharm. 2002 Jul-Aug; 8(4):285-90. PMID: 14613422.
      View in: PubMed
    86. Phillips K, Chen JL. Impact of the U.S. panel on cost-effectiveness in health and medicine. Am J Prev Med. 2002 Feb; 22(2):98-105. PMID: 11818178.
      View in: PubMed